Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers

Diabetes Technology and Therapeutics

Volumn 13, Issue 10, 2011, Pages 1039-1045

  Morrow, Linda ^a   Muchmore, Douglas B ^b   Ludington, Elizabeth A ^b   Vaughn, Daniel E ^b   Hompesch, Marcus ^a  

^a Profil Institute for Clinical Research   (United States)

^b Halozyme Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN LISPRO; PIG INSULIN; RECOMBINANT HYALURONIDASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFUSION RATE; INJECTION SITE BLEEDING; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INSULIN BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYALURONOGLUCOSAMINIDASE; INSULIN LISPRO; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 80053426508     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0115     Document Type: Article

References (23)

1. Becker RH, Frick AD: Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008;47:7-20. (Pubitemid 350260885)
2. Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart. A randomized doubleblind cross-over trial in type 1 diabetes. Diabetes Care 1999;22:801-805. (Pubitemid 29220783)
3. Ulrich H, Snyder B, Garg SK: Combining insulins for optimal blood glucose control in type I and 2 diabetes: Focus on insulin glulisine. Vasc Health Risk Manag 2007;3:245-254. (Pubitemid 47214970)
4. Rossetti P, Porcellati F, Bolli GB, Fanelli CG: Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: The role of insulin analogs. Diabetes Care 2008;31(Suppl 2):S113-S120.
5. Eisenbarth GS: Update in type 1 diabetes. J Clin Endocrinol Metab 2007;92:2403-2407.
6. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T: Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 1997;46:440-443. (Pubitemid 27090273)
7. Davies M: The reality of glycaemic control in insulin treated diabetes: Defining the clinical challenges. Int J Obes Relat Metab Disord 2004;28(Suppl 2):S14-S22. (Pubitemid 39389602)
8. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114: 230-241. (Pubitemid 44291844)
9. Frost GI: Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427-440. (Pubitemid 47249140)
10. Chain E, Duthie ES: Identity of hyaluronidase and spreading factor. Br J Exp Pathol 1941;21:324-338.
11. Forbes GB, Deisher RW: Effect of hyaluronidase on the subcutaneous absorption of electrolytes in humans. Science 1950;111:177-179.
12. Hylenex Recombinant (Hyaluronidase Human Injection) 150 USP Units/mL [prescribing information]. Deerfield, IL: Baxter Healthcare Corp., 2009.
13. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003;289:2254-2264. (Pubitemid 37430194)
14. McAulay V, Frier BM: Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin Pharmacother 2003;4:1141-1156. (Pubitemid 36857194)
15. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI: Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009;11:345-352.
16. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402. (Pubitemid 24064246)
17. Heinemann L, Anderson JH Jr: Measurement of insulin absorption and insulin action. Diabetes Technol Ther 2004;6: 698-718. (Pubitemid 39383074)
18. Soeborg T, Rasmussen CH, Mosekilde E, Colding-Jorgensen M: Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci 2009;36:78-90.
19. Heinemann L: Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-682. (Pubitemid 35283332)
20. Guerci B, Sauvanet JP: Subcutaneous insulin: Pharmacokinetic variability and glycemic variability. Diabetes Metab 2005;31:4S7-4S24. (Pubitemid 41379375)
21. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sørensen AR, Voigt HO: Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988;333:679-682.
22. Richardson T, Kerr D: Skin-related complications of insulin therapy: Epidemiology and emerging management strategies. Am J Clin Dermatol 2003;4:661-667. (Pubitemid 37411982)
23. Dalla MC, Rizza RA, Cobelli C: Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng 2007; 54:1740-1749. (Pubitemid 47450539)